Relationship between PPAR-γ gene polymorphisms and ischemic stroke risk: A meta-analysis

Fan Cheng1 | Xiao-Min Si1,2 | Gong-Li Yang3 | Lan Zhou1,2

1 Center of Cardiopulmonary Rehabilitation, Taihe Hospital, Hubei University of Medicine, Shiyan, China
2 Department of Neurology, Taihe Hospital, Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan, China
3 Department of Gastroenterology, Shenzhen University General Hospital, Shenzhen University, Shenzhen, China

Correspondence
Gong-Li Yang, Department of Gastroenterology, Shenzhen University General Hospital, Shenzhen University, Shenzhen 518055, China. Email: yssz100163@yeah.net
Lan Zhou, Department of Neurology, Taihe Hospital, Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan 442000, China. Email: 1902764052@qq.com

Funding information
Health Commission of Hubei Province Scientific Research, Grant/Award Number: WJ2021M049

Abstract
Background: Published researches have suggested some associations between PPAR-γ and ischemic stroke (IS) development. This meta-analysis was conducted to evaluate the association between PPAR-γ gene polymorphisms and IS risk.

Materials and methods: A systematic search was conducted in PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and WanFang databases. The pooled association of odd ratios (ORs) and its 95% confidence interval (CI) was calculated to assess the IS risk of PPAR-γ rs1801282 C/G and rs3856806 C/T polymorphisms. Furthermore, the heterogeneity test, cumulative analyses, sensitivity analyses, and publication bias were conducted.

Result: Sixteen publications with 3786 cases and 5343 controls were identified. Overall findings indicated that rs1801282 C/G polymorphism may be associated with an increased risk for IS (GG vs. CC: OR = 2.17, 95%CI = 1.09–4.35, p = .03, I² = 0%; GG vs. CC+CG: OR = 2.15, 95%CI = 1.07–4.32, p = .03, I² = 0%). The similar results were also found in the subgroup analysis. In addition, no significant association was observed between rs3856806 C/T polymorphism and IS risk.

Conclusion: In conclusion, our study showed that PPAR-γ rs1801282 C/G polymorphism probably plays an important role in IS occurrence. The result should be verified with more studies in the future.

KEYWORDS
meta-analysis, polymorphism, PPAR-γ, stroke

1 INTRODUCTION

Stroke is one of the most common medical events resulting in disability and death among adults. More than 13.7 million new stroke cases and 5.5 million deaths, in addition to 116.4 million disability-adjusted life years, were recorded worldwide in 2016 alone (Collaborators GBDS, 2019). Ischemic stroke (IS) is considered an atherosclerotic and thromboembolic event that results in decreased blood flow to the brain tissue, leading to subsequent infarction (Feigin et al., 2009). With an increase in the elderly population, the incidence of IS is projected to exhibit a sharp upsurge in the near future. IS, one of the most prevalent cerebrovascular events, has turned into a tragedy for affected individuals, as it brings heavy mental and financial burden for the family and society. This has resulted in a significant decline in the quality of life of patients in both developed and developing countries. Etiology and pathogenesis studies have been extensively conducted on IS; however, the underlying mechanism remains unclear. Cerebrovascular atherosclerosis and secondary ischemic brain injury are the most common risk factors that ultimately result in cerebral thrombosis and IS. Moreover, other factors such as environmental pollution,
hypertension, genetic background, and unhealthy lifestyle habits have additionally been suggested to be associated with IS development. Increasing evidence suggests the existence of a strong polygenic inheritance factor for IS etiology, including abnormal gene expression and genetic mutations.

Peroxisome proliferator-activated receptor-γ (PPAR-γ) belongs to the nuclear receptor superfamily, which mainly mediates ligand-dependent transcriptional activation and repression. PPAR-γ plays a key role in the regulation of adipocyte differentiation, lipid metabolism, and insulin sensitivity in vivo, with PPAR-γ2 exhibiting a higher activity in adipocytes than other types. Accumulating evidence indicates that PPAR-γ participates in the regulation of adipocyte differentiation, lipid metabolism, and the concentration of lipids and cholesterol. Dyslipidemia is a well-established risk factor for cardiovascular diseases, which triggers the development of atherosclerosis and increases the risk of IS risk. PPAR-γ also plays an important role in regulating inflammatory processes, participates in vascular endothelial cell repair, and inhibits thrombosis formation (D. Li et al., 2005). A recent study demonstrated that PPAR-γ agonists exert an active anti-inflammatory effect in IS models and protect against thrombosis by downregulating the activation of nuclear factor-κB and decreasing the expression of proinflammatory cell adhesion molecules (Jin et al., 2015).

The PPAR-γ gene is located on chromosome 3p25, is comprised of 100Kb DNA bases, and consists of nine exons. The rs1801282 C/G and rs3856806 C/T polymorphisms are the most common single nucleotide polymorphism (SNP) loci in the PPAR-γ gene, and have been extensively studied in different ethnic groups and found to be associated with the risk of several metabolic diseases, including diabetes and its complications. This mutation may change the transcriptional activity and subsequently alter the protein synthesis of PPAR-γ (Masugi et al., 2000). This leads to abnormal lipid metabolism and subcellular metabolism in arterial foam cells, resulting in the formation of atherosclerosis and an altered risk of stroke (Grbić et al., 2018). Furthermore, PPAR-γ agonists have been extensively studied as potential neuroprotective agents in recent decades (Kinouchi et al., 2018; Y. Li et al., 2019; Shimazu et al., 2005).

In 2005, Shen and Ha (2005) conducted the first case–control study and found no significant association between the rs1801282 C/G polymorphism and IS risk in a Chinese population. However, study results that followed Shen et al. on genetic associations of this SNP with IS risk have been controversial and inconclusive. Therefore, this meta-analysis was conducted to amalgamate the results of existing studies in order to elucidate the association of rs1801282 C/G and rs3856806 C/T polymorphisms with IS risk.

2 MATERIALS AND METHODS

This meta-analysis was conducted according to the online guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. All collected data were extracted from published studies, and no ethical issue was involved (Moher et al., 2009).

2.1 Literature search

The PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and WanFang databases were explored online, focusing on the association between PPAR-γ polymorphisms and IS susceptibility before April 1, 2021. Research articles published only in English and Chinese were selected for this study. The bibliographies of relevant articles were retrieved for potential studies. The strategy was listed as follows (e.g., in PubMed):

#1 Peroxisome proliferator-activated receptor-γ
#2 PPAR-γ
#3 PPARG
#4 #1 or #2 or #3
#5 rs1801282
#6 rs3856806
#7 Pro12Ala
#8 polymorphism
#9 Variant
#10 Mutation
#11 #5 or #6 or #7 or #8 or #9 or #10
#12 Ischemic stroke
#13 Stroke
#14 #12 or #13
#15 #4 and #11 and #14

2.2 Inclusion and exclusion criteria

The criteria for inclusion of identified studies for the purpose of this meta-analysis were as follows: (1) case–control studies on the association between PPAR-γ rs1801282 C/G, rs3856806 C/T polymorphisms, and IS risk; (2) studies supplying sufficient information on the genotypes in both case and control groups with respect to evaluate the odd ratios (ORs) and 95% confidence intervals (CIs); (3) studies published either in English or Chinese; (4) the polymorphism locus was calculated with at least three studies; and the largest or latest data with more adequate information were collected when duplicate publications or overlapping data were presented. The exclusion criteria were as follows: (1) review articles, case reports, and animal experiments; (2) biological fundamental research; (3) studies without sufficient data; and (4) duplicate or overlapping data on the same theme.

2.3 Data extraction and quality evaluation

Two authors (Cheng and Zhou) independently reviewed the included studies and extracted the relevant information: the first author’ name, year of publication, study country, ethnicity difference, control design, genotyping method, sample sizes of the cases and controls, frequency of the genotype distribution in the cases and control groups, the degree of Hardy–Weinberg equilibrium (HWE) in the control group, minor allele frequency, and Newcastle–Otawa scale (NOS) evaluation. The
NOS was adopted to evaluate the quality of the included studies. The scores ranged from 0 (worst) to 11 (best) (Table 1). Studies with a score of eight points or higher indicate a good research quality.

### 2.4 Statistical analysis

The ORs and 95% CIs were calculated to examine the statistical power between PPAR-γ polymorphisms and IS risk using five genetic models: allelic model (rs1801282: G vs. C; rs3856806: T vs. C), codominant models: heterozygous model (rs1801282: CG vs. CC; rs3856806: CT vs. CC) and homozygous model (rs1801282: GG vs. CC; rs3856806: TT vs. CC), dominant model (rs1801282: CG+GG vs. CC; rs3856806: CT+TT vs. CC), and recessive model (rs1801282: GG vs. CC+CG; rs3856806: TT vs. CC+CT). Heterogeneity among the included studies was examined using Cochrane’s Q and $I^2$ tests. A fixed-effects model was adopted when $I^2$ was ≤40%; otherwise, a random-effects model was adopted. Subgroup analyses were conducted based on ethnic differences, control design, number of subjects, and the HWE status. Subgroup analysis was conducted only if data from at least two studies were available. Meta-regression analysis was performed to identify the potential factors that may have contributed to the heterogeneity. A cumulative meta-analysis was conducted to determine the change in tendencies in the results. Sensitivity analysis was used to examine the stability of the results by removing each study step by step. Publication biases were assessed using Egger’s linear regression test and Begg’s funnel plots. All statistical analyses were performed using the STATA version 14.0 (Stata Corporation, College Station, TX, USA). Statistical significance was set at $p < .05$.

### RESULTS

#### 3.1 Study characteristics

According to the search strategy utilizing a variety of literature retrieval databases, a total of 153 studies were initially identified, of which 73 were excluded for duplications through title and abstract screening. After the full-text review, 64 studies were excluded further (overlapping data [n = 2], other polymorphism loci [n = 3], reviews [n = 3], irrelevant studies [n = 16], and biology studies [n = 38]) (Figure 1). Finally, 16 studies involving 3786 patients and 5343 controls were included in this meta-analysis (Bazina et al., 2015; Chehaibi et al., 2014; L. Huang et al., 2007; Lee et al., 2007, 2006; X. Li et al., 2016; Z. J. Liu et al., 2010; Lu et al., 2009; Shen & Ha, 2005; Sun, 2010; Tong et al., 2015, 2016; Wang et al., 2019; Wei et al., 2013; Yuan, 2008; Zafarmand et al., 2008). Of these, 10 case–control studies focused on rs1801282 C/G polymorphism (Bazina et al., 2015; L. Huang et al., 2007; Lee et al., 2006, 2007; X. Li et al., 2016; Shen & Ha, 2005; Tong et al., 2015, 2016; Wang et al., 2019; Zafarmand et al., 2008) and, seven case–control studies focused on rs3856806 C/T polymorphism (Chehaibi et al., 2014; Z. J. Liu et al., 2010; Lu et al., 2009; Sun, 2010; Wang et al., 2019; Wei et al., 2013; Yuan, 2008). In addition, 13 studies were based on Asian descendants, and three studies were based on European descendants. Four genotype methods were used among these studies, including polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP), TaqMan, multiplex genotyping assay, and SNPshot Multiplex Kit. All of the included characteristics are summarized in Table 1.

#### 3.2 PPAR-γ rs1801282 C/G polymorphism and IS risk

Ten case–control studies involving a total of 2804 patients and 4457 controls were identified for the PPAR-γ rs1801282 C/G polymorphism and IS risk. The results of our meta-analysis revealed a significant risk between the rs1801282 C/G polymorphism of PPAR-γ and IS susceptibility in the general population (GG vs. CC: OR = 2.17 95%CI = 1.09–4.35, $p = .03$, $I^2 = 0%$; GG vs. CC+CG: OR = 2.15, 95%CI = 1.07–4.32, $p = .03$, $I^2 = 0%$) (Table 2). Moreover, significant associations between the rs1801282 C/G polymorphism and IS risk were also found in the subgroups with population-based (PB) controls (GG vs. CC: OR = 2.21, 95%CI = 1.07–4.55, $p = .03$, $I^2 = 0%$; GG vs. CC+CG: OR = 2.19, 95%CI = 1.06–4.53, $p = .03$, $I^2 = 0%$) and among those studies with more than 500 individuals (GG vs. CC: OR = 2.26, 95%CI = 1.26–4.34, $p = .02$, $I^2 = 0%$; GG vs. CC+CG: OR = 3.22, 95%CI = 1.24–8.38, $p = .02$, $I^2 = 0%$) (Table 2).

Cumulative analyses presented a positive result with the studies added to the homozygous and recessive models (Figure 3a for GG vs. CC model; Figure 3b for GG vs. CC+CG model). Sensitivity analyses indicated that the results fluctuated slightly only when the study by Tong et al. (2015) was removed (Figure 4a for GG vs. CC model; Figure 4b for GG vs. CC+CG model). In addition, no significant asymmetrical funnel plot was observed for publication bias among the included studies, which was further verified by Egger’s test (G vs. C: $p = .08$; GG vs. CC: $p = .09$; GG vs. CC+CG: $p = .77$; CG+GG vs. CC: $p = .09$; GG vs. CC+CG: $p = .74$) (Figure 5a for GG vs. CC model; Figure 5b for GG vs. CC+CG model).

#### 3.3 PPAR-γ rs3856806 C/T polymorphism and IS risk

Seven case–control studies, involving 1873 patients and 1769 controls, were identified for the meta-analysis of the association between PPAR-γ rs3856806 C/T polymorphism and IS risk. Our results suggest that there is no significant association between the rs3856806 C/T polymorphism and IS risk (T vs. C: OR = 0.87, 95%CI = 0.59–1.28, $p = .48$, $I^2 = 88.7%$; CT vs. CC: OR = 0.50, 95%CI = 0.59–1.29, $p = .50$, $I^2 = 81.7%$; TT vs. CC: OR = 1.00, 95%CI = 0.45–2.20, $p = 1.00$, $I^2 = 78.8%$; CT+TT vs. CC: OR = 0.86, 95%CI = 0.56–1.32, $p = .49$).
**TABLE 1**  Characteristics of case–control studies on peroxisome proliferator-activated receptor-γ (PPAR-γ) polymorphisms and ischemic stroke risk

| First author | Year | Country | Ethnicity | Control design | Genotype method | Case | Control | Genotype distribution | p for HWE | MAF | NOS evaluation | Matching criteria |
|--------------|------|---------|-----------|----------------|----------------|------|---------|----------------------|-----------|-----|----------------|------------------|
| Rs1801282    |      |         |           |                |                |      |         |                      |           |     |                |                  |
| Shen         | 2005 | China   | Asian     | PB             | PCR-RFLP       | 70   | 95      | CC/CG/GG     | .75       | 0.03| 9              | Healthy check-ups |
| Lee-1        | 2006 | Korea   | Asian     | HB             | PCR-RFLP       | 302  | 424     | 290/12/00    | .31       | 0.05| 10             | Age-matched health and diabetes controls |
| Lee-2        | 2007 | Korea   | Asian     | PB             | PCR-RFLP       | 134  | 129     | 128/6/0      | .58       | 0.05| 10             | Health check-ups  |
| Huang        | 2007 | China   | Asian     | PB             | PCR-RFLP       | 199  | 200     | 171/18/1     | .39       | 0.06| 9              | Healthy check-ups  |
| Zafarmand    | 2008 | Nether- | Caucasian | PB             | Multilocus genotyping assay | 49   | 1519    | 38/10/1      | .52       | 0.13| 10             | NA               |
| Bazina       | 2015 | Croatia | Caucasian | PB             | PCR-RFLP       | 114  | 187     | 84/27/3      | .83       | 0.13| 9              | Sex and age matched healthy staff |
| Tong-1       | 2015 | China   | Asian     | PB             | TaqMan         | 100  | 100     | 80/19/1      | .19       | 0.13| 9              | Age and gender and ethnically matched normal healthy controls |
| Tong-2       | 2016 | China   | Asian     | PB             | TaqMan         | 648  | 648     | 606/40/2     | .51       | 0.05| 10             | Age and gender and ethnically matched normal healthy controls |
| Li           | 2016 | China   | Asian     | HB             | PCR-RFLP       | 302  | 272     | 274/26/2     | .44       | 0.04| 9              | NA               |
| Wang         | 2019 | China   | Asian     | PB             | SNaPshot Multiplex Kit | 895  | 883     | 756/129/10   | .59       | 0.04| 10             | Age- and sex-matched healthy controls |
| Rs3856806    |      |         |           |                |                |      |         |                      |           |     |                |                  |
| Yuan         | 2008 | China   | Asian     | PB             | PCR-RFLP       | 293  | 203     | 150/134/14   | .15       | 0.20| 9              | NA               |
| Lu           | 2009 | China   | Asian     | PB             | PCR-RFLP       | 114  | 120     | 87/23/4      | .72       | 0.23| 9              | Healthy check-ups |
| Liu          | 2010 | China   | Asian     | PB             | PCR-RFLP       | 168  | 165     | 128/36/4     | .26       | 0.21| 8              | Healthy check-ups |
| Sun          | 2010 | China   | Asian     | PB             | PCR-RFLP       | 90   | 94      | 45/42/3      | .16       | 0.21| 9              | Age- and sex-matched healthy check-ups |
| Wei          | 2013 | China   | Asian     | PB             | PCR-RFLP       | 112  | 112     | 87/19/6      | <.01      | 0.19| 8              | Healthy check-ups |
| Chehaibi     | 2014 | Tunisia | Caucasian | PB             | PCR-RFLP       | 196  | 192     | 143/39/14    | <.01      | 0.27| 8              | Individuals with normal glucose |
| Wang         | 2019 | China   | Asian     | PB             | SNaPshot Multiplex Kit | 895  | 883     | 515/322/58   | .13       | 0.18| 10             | Age- and sex-matched healthy controls |

**Note:** Hardy–Weinberg equilibrium (HWE) in control.

**Abbreviations:** HB, hospital-based control; NA, not available; NOS, Newcastle–Ottawa scale; PB, population-based control. PCR-RFLP; polymerase chain reaction–restriction fragment length polymorphism.
**TABLE 2** Summary odd ratios (ORs) and 95% confidence interval (CI) of peroxisome proliferator-activated receptor-γ (PPAR-γ) polymorphism and ischemic stroke risk

| Rs1801282C/G | Allelic model: G vs. C | Codominant model: CG vs. CC | Codominant model: GG vs. CC | Dominant model: CG+GG vs. CC | Recessive model: GG vs. CC+CG |
|--------------|------------------------|-----------------------------|----------------------------|-------------------------------|-----------------------------|
|              | N | OR  | 95% CI | p  | I² (%) | OR  | 95% CI | p  | I² (%) | OR  | 95% CI | p  | I² (%) | OR  | 95% CI | p  | I² (%) |
| Rs1801282C/G |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| Total        | 10 | 0.90  | 0.62–1.29 | .55 | 76.5 | 0.84  | 0.58–1.21 | .35 | 73.2 | 2.17 | 1.09–4.35 | .03 | 0 | 0.86 | 0.59–1.26 | .44 | 75.4 | 2.15 | 1.07–4.32 | .03 | 0 |
| Ethnicity    |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| Asian        | 8 | 0.86  | 0.54–1.37 | .52 | 81.6 | 0.80  | 0.50–1.28 | .35 | 79.1 | 2.65 | 1.11–6.35 | .03 | 4.6 | 0.83 | 0.52–1.33 | .43 | 80.7 | 2.61 | 1.09–6.27 | .03 | 0.9 |
| Caucasian    | 2 | 1.02  | 0.70–1.48 | .92 | 0 | 0.96  | 0.62–1.48 | .86 | 0 | 1.36 | 0.40–4.65 | .62 | 0 | 0.99 | 0.65–1.50 | .96 | 0 | 1.37 | 0.40–4.69 | .61 | 0 |
| Control design |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| PB           | 8 | 0.95  | 0.64–1.41 | .81 | 76.2 | 0.89  | 0.59–1.33 | .56 | 72.7 | 2.21 | 1.07–4.55 | .03 | 0 | 0.92 | 0.61–1.39 | .68 | 75.0 | 2.19 | 1.06–4.53 | .03 | 0 |
| HB           | 2 | 0.71  | 0.25–2.00 | .51 | 83.1 | 0.68  | 0.24–1.89 | .46 | 81.0 | 1.82 | 0.16–20.25 | .62 | NA | 0.69 | 0.24–1.97 | .49 | 82.4 | 1.81 | 0.16–20.04 | .63 | NA |
| Subjects number |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| <500         | 5 | 0.91  | 0.68–1.22 | .53 | 0 | 0.85  | 0.61–1.18 | .34 | 0 | 1.29 | 0.45–3.70 | .63 | 0 | 0.87 | 0.64–1.21 | .41 | 0 | 1.30 | 0.45–3.70 | .63 | 0 |
| ≥500         | 5 | 0.91  | 0.50–1.66 | .75 | 88.3 | 0.85  | 0.46–1.57 | .61 | 86.8 | 3.26 | 1.26–8.43 | .02 | 0 | 0.88 | 0.47–1.64 | .69 | 87.9 | 3.22 | 1.24–8.38 | .02 | 0 |
| rs3856806C/T |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| T vs. C      | 7 | 0.87  | 0.59–1.28 | .48 | 88.7 | 0.88  | 0.59–1.29 | .50 | 81.7 | 1.00 | 0.45–2.22 | 1.00 | 78.8 | 0.86 | 0.56–1.32 | .49 | 86.7 | 1.03 | 0.51–2.08 | .94 | 72.9 |
| CT vs. CC    |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| TT vs. CC    |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| CT+TT vs. CC |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| TT vs. CC+CT |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| HWE status   |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| HWE-yes      | 5 | 1.00  | 0.66–1.52 | .99 | 87.5 | 0.95  | 0.59–1.53 | .83 | 85.3 | 1.46 | 0.66–3.21 | .35 | 61.7 | 0.98 | 0.59–1.61 | .92 | 87.6 | 1.54 | 0.82–2.89 | .18 | 432 |
| HWE-no       | 2 | 0.60  | 0.45–0.80 | <.01 | 0 | 0.69  | 0.47–1.03 | .07 | 0 | 0.46 | 0.26–0.82 | .01 | 0 | 0.61 | 0.43–0.87 | .01 | 0 | 0.50 | 0.28–0.88 | .02 | 0 |
| Ethnicity    |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| Asian        | 6 | 0.94  | 0.64–1.39 | .76 | 86.6 | 0.91  | 0.59–1.40 | .66 | 83.1 | 1.23 | 0.58–2.63 | .59 | 66.4 | 0.92 | 0.58–1.45 | .72 | 86.1 | 1.29 | 0.68–2.43 | .43 | 53.0 |
| Subjects number |              |                 |              |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |              |                 |    |         |
| <500         | 6 | 0.79  | 0.52–1.18 | .25 | 83.2 | 0.80  | 0.50–1.27 | .34 | 79.2 | 0.75 | 0.40–1.39 | .36 | 44.4 | 0.77 | 0.48–1.25 | .30 | 82.6 | 0.73 | 0.48–1.09 | .13 | 20.5 |

Note: I² for Heterogeneity test.

Abbreviations: HB, hospital-based; HWE, Hardy–Weinberg equilibrium; control; PB, population-based.

*Numbers of comparisons.
$I^2 = 86.7\%$; TT vs. CC+CT: OR = 1.03, 95% CI = 0.51–2.08, $p = .94$, $I^2 = 72.9\%$ (Table 2). Moreover, the synthesized result demonstrated a null association between the rs3856806 C/T polymorphism and IS risk in the subgroup analysis.

Cumulative analyses and sensitivity analyses were conducted, and the results indicated a consisted trend without any fluctuation. In addition, no publication bias was observed with symmetrical funnel plots in all five genetic models, which was further verified with the Egger’s test (T vs. C: $p = .17$; CT vs. CC: $p = .30$; TT vs. CC: $p = .16$; CT+TT vs. CC: $p = .26$; TT vs. CC+CT: $p = .11$).

4 | DISCUSSION

According to the World Health Organization (WHO), stroke is one of the leading causes of mortality and disability worldwide and is responsible for approximately 6.1 million deaths in 2019 (World Health Organization, 2020). IS frequently results from the occlusion of cerebral blood vessels, usually caused by thrombosis with blood clot formation or embolism with intracranial stenosis, accounting for approximately 85% of all stroke incidences (Zhou et al., 2019). With an increase in the aging population, the number of IS patients has been increasing in recent years and is predicted to continue, which brings a substantial economic and social burden to the public health system.

Hypertension, hyperlipidemia, hyperglycemia, atherosclerosis, and arterial stenosis have been demonstrated to be the main causes of IS. In addition, smoking, drinking, unhealthy lifestyle habits, and psychosocial stress have additionally been suggested as high-risk factors for the development of IS. Thrombosis caused by atherosclerosis and inflammatory injury of the vascular endothelium is one of the most direct causes of IS and is significantly associated with aberrant expression or dysfunction of the PPAR family. PPAR-$\gamma$ is a member of the nuclear receptor superfamily and a ligand-activated transcription factor which is widely expressed in adipose cells and tissues and plays a critical role in the regulation of adipogenesis metabolism, insulin sensitivity,
energy balance, inflammation, angiogenesis microvascular lesions, and atherosclerosis (Rocha et al., 2015).

In the past decades, PPAR-\(\gamma\) agonists such as cyclooxygenase-2, interleukin-1\(\beta\) (IL-1\(\beta\)), and tumor necrosis factor-\(\alpha\), which are known to decrease the level of inflammation in many IS models, have been shown to attenuate proinflammatory mediators during IS development. In contrast, murine stroke models with PPAR-\(\gamma\) knocked out also present a stronger proinflammatory response with a higher risk of secondary intracerebral hemorrhage (Gliem et al., 2015). Moreover, other studies have shown that pioglitazone decreases the expression of inflammatory cytokines IL-6, IL-1\(\beta\), and monocyte chemoattractant factor-1 and reduces reperfusion injury of the intracranial artery by diminishing the infiltration of M1 macrophages into the cerebral artery. In contrast, the PPAR-\(\gamma\) antagonist GW9662 reversed this protective function, further supporting the anti-inflammatory effect of PPAR-\(\gamma\) (Yang et al., 2020). In addition, PPAR-\(\gamma\) agonists have been suggested to reduce the risk of recurrent stroke and total events of cardiovascular death or stroke by protecting against arteriosclerosis formation and maintaining the stability of carotid plaques (J. Liu & Wang, 2019; Marfella et al., 2006). Modrick et al. (2012) suggested that PPAR-\(\gamma\)

---

**FIGURE 2**  Odd ratios (OR) and 95% confidence interval (CIs) of the associations between peroxisome proliferator-activated receptor-\(\gamma\) (PPAR-\(\gamma\)) rs1801282 C/G polymorphism and ischemic stroke susceptibility (a: GG vs. CC model; b: GG vs. CC+CG model)
Figure 3: Cumulative meta-analyses according to publication year on peroxisome proliferator-activated receptor-γ (PPAR-γ) rs1801282 C/G polymorphism and ischemic stroke susceptibility (a: GG vs. CC model; b: GG vs. CC+CG model)

might play a protective role in vascular aging by protecting against age-induced oxidative stress and endothelial dysfunction. Moreover, PPAR-γ activation is known to enhance angiogenesis and the migration of human brain microvascular endothelial cells through the formation of the fibroblast growth factor-21/fibroblast growth factor receptor-1/β-Klotho complex, and improve the ability of vascular recanalization and nerve repair after stroke (W. Huang et al., 2019). All these lines of evidence demonstrate that PPAR-γ plays an important role in the pathogenesis of IS. However, the underlying pathogenesis of PPAR-γ in the IS remains unclear.

SNPs are one of the most prevalent forms of gene mutations which can influence gene expression and protein activity. In terms of the PPAR-γ gene, rs1801282 C/G and rs3856806 C/T polymorphisms are the most common SNP loci, which have been reported to be involved in various disease susceptibilities in the past decades. In 1997, the rs1801282 C/G polymorphism locus was first reported by Yen et al. (1997). This mutation comprises an exchange of cytosine for guanine, resulting in the substitution of alanine for proline at codon 12 of exon B. The Ala allele reduces the binding affinity to the cognate promoter element as well as promoter activity and transcription of PPAR-γ (Deeb et al., 1998). In 2005, Shen and Ha (2005) conducted the first case-control study focusing on the PPAR-γ gene rs1801282 C/G polymorphism and IS risk in a Chinese population; however, they did not find any significant association between this mutation and IS. Since then, subsequent series of studies have been conducted, and some inconsistent or contradictory results have been reported. Lee et al. (2006) found a potential protective trend of the rs1801282 C/G genotype in IS patients with type 2 diabetes in Korean people (OR = 0.43, p = .025).
CHENG ET AL.

FIGURE 4  Sensitivity analysis when each study was removed with publication year on peroxisome proliferator-activated receptor-γ (PPAR-γ) rs1801282 C/G polymorphism and ischemic stroke susceptibility (a: GG vs. CC model; b: GG vs. CC+CG model)

Tong et al. (2016) additionally reported a protective effect against IS formation in a Chinese population. In contrast, another study by Wang et al. (2019) demonstrated that the G allele presented a significantly higher frequency of the rs1801282 polymorphism than that in the control group and carried a 1.844-fold increased risk of IS (OR = 1.844, p < .001). However, most studies have suggested that there is no significant correlation between this mutation and IS risk (Bazina et al., 2015; L. Huang et al., 2007; Zafarmand et al., 2008). Ethnic differences, small sample sizes of studies, and differences in scientific research approaches and qualities of data may be the main reasons for the inconsistent conclusions among previous studies.

Meta-analysis is a useful statistical method that combines quantitative methods with synthetic data from published studies and draws conclusions on the same theme. For the PPAR-γ gene, the rs1801282 C/G polymorphism could result in a missense mutation and lead to an amino acid change from proline to alanine. This alteration could reduce the transcriptional activity and regulate the lipoprotein lipase activity, thereby affecting the removal of triglycerides, which leads to atherosclerosis due to dyslipidemia (Schneider et al., 2002). Therefore, we conducted this meta-analysis with 10 case–control studies to assess the precise association between the PPAR-γ rs1801282 polymorphism and IS susceptibility. Overall, the synthesized data suggested that there were significant associations between the rs1801282 polymorphism and IS susceptibility in the homozygous and recessive models. Additionally, ethnic stratification indicated that there was a significant increase in IS risk in Asians with the above-
FIGURE 5  Funnel plot analysis for detect publication bias on peroxisome proliferator-activated receptor-$\gamma$ (PPAR-$\gamma$) rs1801282 C/G polymorphism and ischemic stroke susceptibility (a: GG vs. CC model; b: GG vs. CC+C model). Circles represent the weight of the studies.

mentioned genotypes. These results indicate that the polymorphism locus may play an important role in the occurrence of IS, along with other environmental factors. Furthermore, the differences in ethnicity may be a positive factor contributing to the increased risk in Asians, suggesting that this rs1801282 polymorphism could be involved in IS susceptibility in specific races.

In terms of the PPAR-$\gamma$ gene rs3856806 C/T polymorphism, this mutation is located in exon 6 and results in a substitution of cytosine for thymine, which causes a synonymous mutation with histidine. A previous study reported that although this polymorphism was a silent mutation locus, it still presented a protective effect on atherosclerotic lipid profiles in various cardiovascular diseases. Chehaibi et al. (2014) and other researchers found a significant reduction in serum triglyceride and apolipoprotein B levels in T allele carriers in IS patients. In addition, Matsunaga et al. (2020) also reported that participants with the TT genotype of C/T polymorphism presented with a 45% lower risk of high low-density lipoprotein cholesterol and a 42% lower risk of dyslipidemia. This evidence indicates that rs3856806 C/T reduces the risk of hyperlipidemia and further diminishes the risk of atherosclerotic vessels and IS in patients with type 2 diabetes mellitus. However, the exact role of the rs3856806 C/T polymorphism in IS risk was not consistent in published articles. Lu et al. and others believed that the T allele of the rs3856806 C/T polymorphism had a protective effect against IS occurrence (Z. J. Liu et al., 2010; Lu et al., 2009; Wei et al., 2013). In contrast, Yuan (2008) and Wang et al. (2019) observed an increased risk of IS in individuals with T polymorphism. However, the remaining studies showed that there was no clear correlation between this polymorphism and IS risk (Sun, 2010; Wei et al., 2013). In the current meta-analysis, we found no statistically significant association between this polymorphism and IS risk (Sun, 2010; Wei et al., 2013). In the current meta-analysis, we found no statistically significant association between this polymorphism and IS risk in the general analysis. Moreover, a similar result of no association was observed in the ethnic and other subgroups. The current results indicate that the single-site mutation is not sufficient to affect the susceptibility to IS.

To our knowledge, this study is the first meta-analysis to focus on PPAR-$\gamma$ gene polymorphisms (rs1801282 C/G and rs3856806 C/T) and IS risk. Some advantages exist in this study that help to improve the stability and credibility of the results: (1) a comprehensive and scientific retrieval strategy was used to collect complete information; (2) the current study included a large sample size with all published studies to date; (3) rigorous and accurate methods, including the NOS evaluation,
HWE test, cumulative/sensitivity analyses, and publication bias were used one at a time; and (4) subgroup analyses in two polymorphism loci were conducted to explore potential associations. Inevitably, there are certain limitations that need to be addressed: (1) only two polymorphism loci were examined in this study separately, and the interaction mechanism between loci and heterozygous/homozygous state was not involved; (2) we incorporated studies that mainly originated from Asian and European countries, and the number of collected studies or participants from each study was insufficient, which may lead to uncertainty and variations in results; (3) This study was based on unadjusted data, and other environmental exposure factors, such as serum triglyceride, blood pressure, and body mass index were not involved, which limits our understanding of the underlying mechanisms; and (4) some moderate heterogeneity was observed in genetic models among two polymorphism loci, which might affect the reliability and accuracy of the results.

5 | CONCLUSION

In summary, this meta-analysis suggests that the PPARγ rs1801282 C/G polymorphism may be associated with IS risk in Asians. More studies with larger sample sizes in different ethnic backgrounds are needed to either refute or verify the current conclusions in the future.

ACKNOWLEDGMENT

This study was supported by the Health Commission of Hubei Province Scientific Research project (No. WJ2021M049).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Fan Cheng, Xiao-Min Si, and Lan Zhou conceived the study. Fan Cheng and Xiao-Min Si searched the databases and extracted the data. Xiao-Min Si and Gong-Li Yang analyzed the data. Fan Cheng, Xiao-Min Si, and Gong-Li Yang wrote the draft of the paper. Lan Zhou reviewed the proof. All of the authors approved the final manuscript.

DATA AVAILABILITY STATEMENT

All data collected or analyzed for this study are available from the corresponding author upon reasonable request to any researchers.

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1002/brb3.2434

ORCID

Lan Zhou https://orcid.org/0000-0003-2800-855X

REFERENCES

Bazina, A., Sertic, J., Mismas, A., Lovric, T., Poljakovic, Z., & Milicic, D. (2015). PPARgamma and IL-6 - 174G>C gene variants in Croatian patients with ischemic stroke. Gene, 560(2), 200–204. https://doi.org/10.1016/j.gene.2015.02.003

Bots, M. (2008). Peroxisome proliferator-activated receptor gamma-2, P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: A case-cohort study and meta-analyses. Vascular Health and Risk Management, 4(2), 427–436. https://doi.org/10.2147/vhrm.s2397

Chehaibi, K., Nouira, S., Mahdouani, K., Hamdi, S., Roui, M., & Slimane, M. N. (2014). Effect of the PPARgamma C161T gene variant on serum lipids in ischemic stroke patients with and without type 2 diabetes mellitus. Journal of Molecular Neuroscience, 54(4), 730–738. https://doi.org/10.1007/s12031-014-0326-3

Collaborators GBDS. (2019). Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(5), 439–458. https://doi.org/10.1016/S1474-4422(19)30034-1

Deeb, S. S., Fajas, L., Nemoto, M., Pihlajamäki, J., Mykkänen, L., Kuusisto, J., Laakso, M., Fujimoto, W., & Auwerx, J. (1998). A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics, 20(3), 284–287. https://doi.org/10.1038/3099

Feigin, V. L., Lawes, C. M., Bennett, D. A., Barker-Collo, S. L., & Parag, V. (2009). Worldwide stroke incidence and early case fatality reported in 56 population-based studies: A systematic review. The Lancet Neurology, 8(4), 355–369. https://doi.org/10.1016/S1474-4422(09)70025-0

Gliem, M., Klotz, L., Van Rooijen, N., Hartung, H.-P., & Jander, S. (2015). Hyperglycemia and PPARgamma antagonistically influence macrophage polarization and infarct healing after ischemic stroke. Stroke: A Journal of Cerebral Circulation, 46(10), 2935–2942. https://doi.org/10.1161/STROKEAHA.115.010557

Grbić, E., Peterlin, A., Kunej, T., & Petrović, D. (2018). PPAR gene and Grb10 expression in response to ischemic stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(7), 1410–1417. https://doi.org/10.1161/ATVBAHA.117.309477

Huang, L., Gu, W. P., Li, W., Wang, N. N., Song, X. M., Wang, Y. Z., & Peng, Y. Q. (2007). Relationship between PPARr2 gene pro12ala polymorphism and cerebral infarction (Chinese). Practical Preventive Medicine, 14(2), 289–291. https://doi.org/10.3969/j.issn.1006-3110.2007.02.011

Huang, W., Shao, M., Liu, H., Chen, J., Hu, J., Zhu, L., Liu, F., Wang, D., Zou, Y., Xiong, Y., & Wang, X. (2019). Fibroblast growth factor 21 enhances angiogenesis and wound healing of human brain microvascular endothelial cells by activating PPARgamma. Journal of Pharmacological Sciences, 140(2), 120–127. https://doi.org/10.1016/j.yphs.2019.03.010

Jin, H., Gebska, M. A., Blokhin, I. O., Wilson, K. M., Ketsawatsomkron, P., Chauhan, A. K., Keen, H. L., Sigmund, C. D., & Lentz, S. R. (2015). Endothelial PPAR-gamma protects against vascular thrombosis by downregulating P-selectin expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(4), 838–844. https://doi.org/10.1161/ATVBAHA.115.305378

Kinouchi, T., Kitazato, K. T., Shimada, K., Yagi, K., Tada, Y., Matsushita, N., Kurashiki, Y., Satomi, J., Sata, M., & Nagahiro, S. (2018). Treatment with the PPARgamma agonist pioglitazone in the early post-ischemia phase inhibits pro-inflammatory responses and promotes neurogenesis via the activation of innate- and bone marrow-derived stem cells in rats. Translational Stroke Research, 9(3), 306–316. https://doi.org/10.1007/s12975-017-0577-8

Lee, B.-C., Doo, H.-K., Ahn, S.-Y., Byun, S.-H., Kim, S.-I., Park, H.-K., Hong, M., Ha, E., Yim, S.-Y., Yin, C., Leem, K.-H., & Ahn, Y.-M. (2007). Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism is associated with the susceptibility to ischemic stroke in Taeasumin classified by Sasang medicine. Neurological Research, 29(Suppl 1), 32–37. https://doi.org/10.1179/1616410717X127347

Lee, B. C., Lee, H.-J., & Chung, J.-H. (2006). Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neuroscience Letters, 410(2), 141–145. https://doi.org/10.1016/j.neulet.2006.08.024

Li, D., Chen, K., Sinha, N., Zhang, X., Wang, Y., Sinha, A., Romeo, F., & Mehta, J. (2005). The effects of PPAR-gamma ligand pioglitazone on platelet
aggregation and arterial thrombus formation. Cardiovascular Research, 69(4), 907–912. doi:10.1016/j.cardiores.2004.11.027

Li, Y., Ren, T., Xu, L., Wang, Y., Yang, B., Luo, H., Zeng, Z., Zhang, Y., Du, G., Zhu, M., & Zhou, J. (2019). Propane-2-sulfonic acid octadec-9-ynylamide, a novel peroxisome proliferator-activated receptors alpha and gamma dual agonist, enhances hippocampal neurogenesis and neuroplasticity in rats with cerebral ischaemia. NeuroReport, 30(18), 1299–1306. https://doi.org/10.1097/WNR.0000000000001360

Li, X., Zhang, B. L., Zhang, X. G., & Su, X. L. (2016). Correlation between PPARG2 gene Pro12Ala polymorphism and cerebral infarction in an Inner Mongolian Han Chinese population. Genetics and Molecular Research: GMR, 15(2), gmr.15027332. https://doi.org/10.4238/gmr.15027332

Liu, J., & Wang, L.-N. (2019). Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. The Cochrane Database of Systematic Reviews, 10, CD010693. https://doi.org/10.1002/14651858.CD010693.pub5

Liu, Z. J., Zhang, Y. D., Chen, J., Cao, G. F., Yang, X. D., Xu, S., Tian, C. H., J. L., Song, C., & Yang, Y. Q. (2010). Relationship between PPARG C161T gene polymorphisms and atherosclerotic cerebral infarction (Chinese). China Journal of Modern Medicine, 20(3), 3595–3597.

Lu, D., Lu, X. C., Tan, Z. J., Wei, S.-G., & Luo, B. (2009). Relationship between PPARG γ c161 → T gene polymorphism and cerebral infarction in Zhejiang nationality of Western Guangxi (Chinese). Guangdong Medical Journal, 30(8), 1110–1111. https://doi.org/10.3969/j.issn.1001-9448.2009.08.039

Marfella, R., D’amico, M., Di Filippo, C., Baldi, A., Siniscalchi, M., Sasso, F. C., Portoghese, M., Carbonara, O., Cresczeni, B., Sangiuolo, P., Nicoletti, G. F., Rossiello, R., Ferraraccio, F., Cacciapuoti, F., Verza, M., Coppola, L., Rossi, F., & Paolillo, G. (2006). Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: Effects of rosiglitazone treatment. Journal of the American College of Cardiology, 47(12), 2444–2455. https://doi.org/10.1016/j.jacc.2006.01.073

Masugi, J., Tamori, Y., Mori, H., Koike, T., & Kasuga, M. (2000). Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochemical and Biophysical Research Communications, 268(1), 178–182. https://doi.org/10.1006/bbrc.2000.2096

Matsunaga, T., Naito, M., Yin, G., Hishida, A., Okada, R., Kawai, S., Sasakabe, M., Shimazu, T., Inoue, I., Araki, N., Asano, Y., Sawada, M., Furuya, D., Nagoya, H., & Greenberg, J. H. (2005). A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke; A Journal of Cerebral Circulation, 36(2), 353–359. https://doi.org/10.1161/01.STR.0000152271.21943.a2

Sun, W. M. (2010). Association between PPARG γ gene polymorphisms and cerebral infarction [M]. Hebei Medical University, https://doi.org/10.7665/dy1800253

Tong, Y., Cai, L., Han, S., Lu, Q., Guan, X., Ying, X., Hou, S., Zhan, F., Cheng, J.-Q., & Liu, J. (2016). Functional genetic variants of PPARG383B and PPARGalpha encoding peroxisome proliferator-activated receptors and susceptibility to ischemic stroke in Chinese Han population. Cerebrovascular Diseases, 41(1-2), 96–99. https://doi.org/10.1159/000442306

Tong, Y., Lu, Q., Zhang, Y., Zhan, F., Cai, L., Guan, X., Ying, X., Lu, Z., Liu, J., & Cheng, J. (2015). Association of functional genetic variants in PPARGamma and PPARGalpha encoding peroxisome proliferator-activated receptors with ischemic stroke in a unique Chinese population. International Journal of Cardiology, 190, 205–207. https://doi.org/10.1016/j.ijcard.2015.04.105

Wang, Y.-Z., Zhang, H.-Y., Liu, F., Li, L., Deng, S.-M., & He, Z.-Y. (2019). Association between PPARG genetic polymorphisms and ischemic stroke risk in a northern Chinese Han population: A case-control study. Neuroregeneration Research, 14(11), 1986–1993. https://doi.org/10.4320/1673-5374.259621

Wei, W. M., Li, S. T., & Huang, S. (2013). Correlation between PPARGY C161T polymorphisms and atherothrombotic infarction in a Chinese Han population (Chinese). International Journal of Cerebrovascular Diseases, 21(5), 353–356.

World Health Organization. WHO | The top 10 causes of death. (2020). http://www.who.int/mediacentre/factsheets/fs310/en/

Yang, Y., Wei, C., Liu, J., Ma, D., Xiong, C., Lin, D., & Wu, A. (2020). Atorvastatin protects against postoperative neurocognitive disorder via a peroxisome proliferator-activated receptor-gamma signaling pathway in mice. The Journal of International Medical Research, 48(5), 0300060520924245. https://doi.org/10.1177/0300060520924251

Yen, C.-J., Beamer, B. A., Negri, C., Silver, K., Brown, K. A., Yarnall, D. P., Dou, E., Glenn, S., Krish, V. S., Miller-Petrie, M. K., ... Liang, X. (2019). Propane-2-sulfonic acid octadec-9-ynylamide, a novel peroxisome proliferator-activated receptor-gamma 2 gene polymorphism in patients with metabolic syndrome. Archives of Endocrinology and Metabolism, 59(4), 297–302. doi:10.1590/2359-3997000000086

Schneider, J., Kreuzer, J., Hamann, A., Nawroth, P. P., & Dugi, K. A. (2002). The proline 12 alanine substitution in the peroxisome proliferator–activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes, 51(3), 867–870. https://doi.org/10.2337/diabetes.51.3.867

Shen, D., & Ha, D.-W. (2005). Relationship between PPARY gene Pro12Ala polymorphism and hypertension complicated with cerebral infarction in the elderly (Chinese). Chinese Journal of Gerontology, 25(3), 235–237. https://doi.org/10.3969/j.issn.1005-9220.2005.03.002

Shimazu, T., Inoue, I., Araki, N., Asano, Y., Sawada, M., Furuya, D., Nagoya, H., & Greenberg, J. H. (2005). A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke; A Journal of Cerebral Circulation, 36(2), 353–359. https://doi.org/10.1161/01.STR.0000152271.21943.a2

How to cite this article: Cheng, F., Si, X.-M., Yang, G.-L., & Zhou, L. (2021). Relationship between PPARY gene polymorphisms and ischemic stroke risk: A meta-analysis. Brain and Behavior, 11, e2434. https://doi.org/10.1002/brb3.2434